Since the appointment of Bruno Holthof as Chairman of the Board of Directors of the company in April 2025, the company's board has continued to strengthen its expertise in the biopharma field.
EQS Voting Rights Announcement: EVOTEC SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group.
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 0.50% to 44,565.39 while the NASDAQ rose 0.60% to 21,020.67. The S&P 500 also rose, gaining, 0.53% to 6,330.03. Communication services shares jumped by 1.4% on ...
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of Evotec SE EVO fell sharply in pre-market trading after the company updated its revenue guidance for the fiscal year 2025.